Key Ideas
Low-grade serous ovarian cancer behaves nothing like its high-grade counterpart: it is rarer, affects younger patients, and resists standard chemotherapy. A newly reported phase 3 trial confirms chemotherapy followed by maintenance letrozole as the frontline standard, while two newer options, trametinib and the avutometinib-defactinib combination, now expand what is offered at relapse.
A Rare Cancer That Plays by Different Rules
High-grade serous carcinoma accounts for roughly 75% of epithelial ovarian cancers. Low-grade serous carcinoma makes up only about 5%. Under the microscope, low-grade serous tumors show mild to moderate atypia rather than the aggressive features of high-grade disease. The two are driven by different biology: low-grade serous carcinoma is typically hormone receptor-positive and driven by activation of the MAPK pathway, most often through KRAS mutations, rather than the TP53 mutations and chromosomal chaos that define high-grade disease. Patients tend to be younger, and the disease is notably chemoresistant, which places surgery, rather than chemotherapy, at the center of upfront management.
That combination, young patients, a rare diagnosis, and a tumor that does not respond well to standard chemotherapy, has meant this disease has been historically underexplored. That has started to change. At the most recent Society of Gynecologic Oncology (SGO) Annual Meeting, two of five plenary presentations focused specifically on low-grade serous ovarian cancer.
A Practice-Defining Frontline Trial
For decades, adjuvant treatment for stage II to IV low-grade serous carcinoma has generally meant platinum-based chemotherapy followed by maintenance letrozole, an aromatase inhibitor, reflecting the tumor's frequent hormone receptor positivity. The phase 3 NRG-GY019 trial tested whether letrozole monotherapy could replace chemotherapy altogether, sparing patients from a treatment they respond to poorly anyway.
It could not. The trial closed early after crossing a prespecified futility boundary: letrozole alone did not demonstrate non-inferiority to chemotherapy followed by letrozole for progression-free survival. Twelve-month progression-free survival rates were 91% with chemotherapy plus letrozole against 80% with letrozole alone. The result establishes, for the first time in a phase 3 setting, a definitive frontline standard for this rare cancer: platinum-based chemotherapy for six cycles, followed by maintenance letrozole.
Recurrence Brings a Biomarker Question, Not a Clear Answer
At relapse, options split roughly into biomarker-directed and non-biomarker-directed therapies, and there is little prospective data on how to sequence one against the other. Two newer agents deserve particular attention.
Trametinib for Broad Recurrent Disease GOG 281 compared the MEK inhibitor trametinib against physician's choice standard of care in recurrent low-grade serous carcinoma. Trametinib improved median progression-free survival to 13.0 months, versus 7.2 months with standard therapy, and improved objective response rate to 26%, versus 6%. Notably, benefit was not confined to patients with MAPK pathway mutations; response occurred across mutation status, which broadens its use to patients without a clear actionable biomarker. The most common toxicities include dermatologic reactions (a diffuse rash requiring proactive skin care, sun protection, and nail hygiene) and diarrhea, both manageable with anticipatory counseling.
Avutometinib Plus Defactinib for KRAS-Mutant Disease The GOG-3052/RAMP 201 trial paired avutometinib, a RAF/MEK clamp inhibitor, with defactinib, a FAK inhibitor, specifically in patients with recurrent disease. In the KRAS-mutant subgroup, the confirmed overall response rate reached 44%, supporting the combination's accelerated FDA approval for KRAS-mutated recurrent disease after prior systemic therapy. Elevated creatine phosphokinase is a common and generally low-grade laboratory finding requiring monitoring and dose adjustment rather than discontinuation; skin toxicity and visual disturbances also warrant baseline counseling and periodic ophthalmologic follow-up.
Where the Standard Platinum-Resistant Playbook Falls Short Two other regimens that have transformed care in platinum-resistant high-grade serous ovarian cancer deserve a caveat here: mirvetuximab soravtansine (studied in SORAYA and MIRASOL) and the KEYNOTE-B96/ENGOT-ov65 combination of pembrolizumab plus weekly paclitaxel with or without bevacizumab both specifically excluded, or barely included, low-grade histology. KEYNOTE-B96 enrolled low-grade serous carcinoma as only about 3% of its population. The National Comprehensive Cancer Network (NCCN) guidelines still list both as reasonable options for appropriate candidates, including folate receptor-positive disease, but the supporting trial data were generated almost entirely in high-grade tumors. Sequencing Without a Playbook With no randomized data comparing these newer options head to head, or clarifying whether biomarker-directed therapy should precede non-biomarker-directed regimens, sequencing decisions rest on individual disease biology and prior exposures. A reasonable framework: confirm hormone receptor, KRAS mutation, and folate receptor status at diagnosis and at recurrence; favor avutometinib-defactinib when a KRAS mutation is present; consider trametinib when no actionable mutation is identified or after progression on the combination; and reserve the platinum-resistant, high-grade-derived regimens for patients who have exhausted disease-specific options or who have overlapping eligibility.
For Patients
Low-grade serous ovarian cancer is different from the more common high-grade form. It tends to occur in younger women, grows more slowly, and does not respond as well to standard chemotherapy, which is why surgery plays such a central role in treatment. New research confirms that chemotherapy followed by a maintenance pill called letrozole remains the best initial approach after surgery.
If the cancer returns, ask whether tumor testing has identified a KRAS mutation, since this can open the door to a newer combination therapy (avutometinib plus defactinib) with a substantially higher response rate. Even without that specific mutation, a drug called trametinib has shown benefit across a broad range of patients with recurrent disease. Because this cancer is rare, treatment decisions benefit from being made in consultation with a gynecologic oncologist experienced with it, and enrollment in a clinical trial is often worth discussing at each point in the disease course.
Key Takeaways
- The phase 3 NRG-GY019 trial confirms platinum-based chemotherapy followed by maintenance letrozole, not letrozole alone, as the definitive frontline standard for stage II to IV low-grade serous ovarian cancer.
- Trametinib (GOG 281) improved progression-free survival to 13.0 months versus 7.2 months with standard therapy in recurrent disease, regardless of mutation status.
- Avutometinib plus defactinib (GOG-3052/RAMP 201) achieved a 44% response rate in KRAS-mutant recurrent disease and has accelerated FDA approval for that population.
- Regimens developed for platinum-resistant high-grade serous ovarian cancer, including mirvetuximab soravtansine and pembrolizumab-based combinations, were studied in populations that excluded or barely included low-grade histology.
- No prospective data guide the sequencing of these newer, disease-specific options against one another or against therapies developed for high-grade disease.
References
- Fader AN, Miller A, Gien L, et al. Results of a randomized phase III trial of letrozole alone versus paclitaxel and carboplatin followed by letrozole as initial treatment for patients with stage II-IV ovarian, fallopian tube, or primary peritoneal low-grade serous carcinoma (NRG-GY019, NCT04095364). Presented at: 2026 SGO Annual Meeting on Women's Cancer; April 10-13, 2026; San Juan, PR.
- Gershenson DM, Miller A, Brady WE, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-553.
- Grisham RN, Nieuwenhuysen EV, Santin AD, et al. Efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol. 2025.
- FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. U.S. Food and Drug Administration. May 8, 2025.
- Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436-2445.
- Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162-2174.
- Colombo N, Zsiros E, Parma G, et al. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2026.
